Orexigen Therapeutics, Inc.

San Diego, California, United States curraxpharma.com

Overview

Orexigen Therapeutics, Inc. was a biopharmaceutical company focused on developing pharmaceutical products for the treatment of obesity. The company's main product was Contrave, a combination drug that was intended to help patients with weight management. Orexigen faced financial challenges and eventually entered bankruptcy proceedings.

Therapeutic areas

ObesityWeight Management

FDA compliance signals

2 FDA enforcement records linked to this company.

  • recall — Class III2018-11-14

    Container packaging defect.

  • recall — Class III2018-08-22

    Defective Container: Customer complaints of punctures in the bottle.

Related companies

MetaboLife Pharmaceuticals Inc.
United States
Helicore Biopharma, Inc.
United States
Metabolic Research Institute, Inc.
United States
Moonwalk Biosciences
United States
Novo Nordisk Inc.
United States
Beijing Ql Biopharmaceutical Co., Ltd.
China
Novo Nordisk A/S
Denmark
10x Genomics, Inc.
United States

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo